<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pmed.1002735.t002" orientation="portrait" position="float">
 <object-id pub-id-type="doi">10.1371/journal.pmed.1002735.t002</object-id>
 <label>Table 2</label>
 <caption>
  <title>Epidemiological comparison of the four diseases considered.</title>
 </caption>
 <alternatives>
  <graphic id="pmed.1002735.t002g" xlink:href="pmed.1002735.t002" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <table frame="hsides" rules="groups">
   <colgroup span="1">
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
   </colgroup>
   <thead>
    <tr>
     <th align="left" rowspan="1" colspan="1">Features</th>
     <th align="left" rowspan="1" colspan="1">Malaria</th>
     <th align="left" rowspan="1" colspan="1">TB</th>
     <th align="left" rowspan="1" colspan="1">Leprosy</th>
     <th align="left" rowspan="1" colspan="1">HIV/AIDS</th>
    </tr>
   </thead>
   <tbody>
    <tr>
     <td align="center" rowspan="1" colspan="1">
      <bold>Transmission</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">Caused by the 
      <italic>Plasmodium</italic> parasite and spread to people through the bites of infected female 
      <italic>Anopheles</italic> mosquitoes. There are five parasite species (including 
      <italic>P</italic>. 
      <italic>falciparum</italic> and 
      <italic>P</italic>. 
      <italic>vivax</italic>) that cause malaria in humans [
      <xref rid="pmed.1002735.ref005" ref-type="bibr">5</xref>].
      <break/>There is no animal reservoir in nature.
     </td>
     <td align="left" rowspan="1" colspan="1">Caused by a bacterium (
      <italic>Mycobacterium tuberculosis</italic>) and most often affects the lungs. Spread from persons with active infection through droplets in the air. Approximately one third of the world’s population has latent TB (long-term asymptomatic infection), but they have only a 10% lifetime risk of becoming sick with TB. If not treated, each person with active TB infects on average 10 to 15 people each year [
      <xref rid="pmed.1002735.ref006" ref-type="bibr">6</xref>]. The proportion of human cases of TB caused by 
      <italic>M</italic>. 
      <italic>bovis</italic> (bovine TB) is estimated at &lt;5% [
      <xref rid="pmed.1002735.ref007" ref-type="bibr">7</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Caused by a bacterium (
      <italic>M</italic>. 
      <italic>leprae</italic>). Transmission is favoured by close contact. May be transmitted from nasal mucosa, possibly through respiratory secretions, but the exact mechanism is not clearly understood. Over 85% of clinical cases are noninfectious. Evidence suggests infectiousness is lost in most instances within a few days of beginning MDT [
      <xref rid="pmed.1002735.ref008" ref-type="bibr">8</xref>]. Zoonotic transmission of leprosy from armadillos to humans has been recorded in the Southern United States and parts of South America [
      <xref rid="pmed.1002735.ref009" ref-type="bibr">9</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Caused by the human immunodeficiency virus; left untreated (2 to 15 years postinfection), acquired immunodeficiency syndrome (AIDS) develops. HIV is transmitted person to person by unprotected sexual intercourse; use of HIV-contaminated injecting and skin-piercing equipment; vertically from mother to infant during pregnancy, delivery, or breastfeeding; or transfusion of infected blood or its components [
      <xref rid="pmed.1002735.ref010" ref-type="bibr">10</xref>].
     </td>
    </tr>
    <tr>
     <td align="center" rowspan="1" colspan="1">
      <bold>Who is at risk?</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">Those at highest risk of severe disease are those with the lowest immunity: infants and young children, pregnant women and patients with HIV/AIDS, nonimmune migrants, mobile populations, and travellers. Seventy percent of malaria deaths occur in children under 5 years [
      <xref rid="pmed.1002735.ref005" ref-type="bibr">5</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Active TB mostly affects adults in their productive years. People who are infected with HIV are 20 to 30 times more likely to develop active TB. The risk of active TB is also greater in persons suffering from malnutrition or diabetes, and smokers [
      <xref rid="pmed.1002735.ref006" ref-type="bibr">6</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Persons at highest risk live in endemic areas in close contact with multibacillary cases. Genetic factors play a part in determining the risk of disease [
      <xref rid="pmed.1002735.ref011" ref-type="bibr">11</xref>]. Leprosy reactions may be masked in patients with advanced HIV disease. Children under 14, as well as older adults, may be at particular risk of leprosy infection [
      <xref rid="pmed.1002735.ref012" ref-type="bibr">12</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Heterosexual sexual transmission is the predominant mode of HIV transmission in the sub-Saharan Africa and South-East Asia regions, with young women particularly vulnerable. Many epidemics are occurring among high-risk groups, including sex workers and men who have sex with men. Injecting drug use is a major mode of transmission in Eastern Europe and Central Asia. Without preventive interventions, the likelihood of transmission from infected mothers to their children is 15%–45% [
      <xref rid="pmed.1002735.ref013" ref-type="bibr">13</xref>].
     </td>
    </tr>
    <tr>
     <td align="center" rowspan="1" colspan="1">
      <bold>Disease burden</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">In 2017, ongoing malaria transmission was present in 90 countries and areas. There were an estimated 219 million cases of malaria, 435,000 deaths, and the incidence rate of malaria was estimated at 63 cases per 1,000 population at risk. A total of 92% of malaria cases are in Africa and 93% of malaria deaths. 
      <italic>P</italic>. 
      <italic>falciparum</italic> is the most prevalent malaria parasite in sub-Saharan Africa, accounting for 99% of estimated malaria cases [
      <xref rid="pmed.1002735.ref005" ref-type="bibr">5</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Over 95% of cases and deaths are in LMICs. In 2016, 45% of new cases occurred in Asia, and 25% in Africa. A total of 74% of people coinfected with TB-HIV in 2016 live in Africa [
      <xref rid="pmed.1002735.ref006" ref-type="bibr">6</xref>].
      <break/>Globally in 2016, there were an estimated 1.7 billion people infected with TB and an estimated 10.4 million incident cases of TB (range, 8.8 million to 12.2 million), equivalent to 140 cases per 100,000 population [
      <xref rid="pmed.1002735.ref014" ref-type="bibr">14</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">In 2017, the estimated global prevalence of leprosy was 0.25 per 10,000 population, and the rate of detection of new cases was 2.77 per 100,000 population [
      <xref rid="pmed.1002735.ref015" ref-type="bibr">15</xref>]. In 2015, India reported 127,326 newly diagnosed cases (60% of those reported globally); Brazil reported 26,395 (13% of those reported globally); and Indonesia reported 17,202 (8% of those reported globally) [
      <xref rid="pmed.1002735.ref016" ref-type="bibr">16</xref>]. The majority of countries with a high number of newly diagnosed cases are located in the Africa and South-East Asia WHO regions.
     </td>
     <td align="left" rowspan="1" colspan="1">Approximately 36.9 million people were living with HIV at the end of 2017 globally, and 1.8 million people became newly infected with HIV in 2017. Sub-Saharan Africa is the most affected region, with 25.7 million people living with HIV in 2017. The WHO Africa region accounts for over two thirds of the global total of new HIV infections each year. Current estimates suggest that 75% of people living with HIV know their status [
      <xref rid="pmed.1002735.ref017" ref-type="bibr">17</xref>].
     </td>
    </tr>
    <tr>
     <td align="center" rowspan="1" colspan="1">
      <bold>Prevention</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">Vector control by use of insecticide-treated mosquito nets and indoor residual spraying.
      <break/>Intermittent preventative treatment for pregnant women and infants in areas of moderate to high malaria transmission in Africa.
      <break/>Seasonal malaria chemoprevention in children under the age of 5 years in areas of high seasonal transmission in the Sahel, Africa [
      <xref rid="pmed.1002735.ref005" ref-type="bibr">5</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Early diagnosis and treatment to stop transmission, chemoprophylaxis for latent TB in young children and those coinfected with HIV or immunocompromised, and BCG vaccine [
      <xref rid="pmed.1002735.ref014" ref-type="bibr">14</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Early detection and prompt MDT of cases, and evaluation and treatment of infected household contacts. Early detection and treatment with MDT has prevented about 4 million people from becoming disabled [
      <xref rid="pmed.1002735.ref008" ref-type="bibr">8</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Safer sexual behaviour, including male and female condom use; testing and counselling for HIV and STIs; medical male circumcision; ARV drug use for prevention (pre-exposure prophylaxis) and treatment as prevention; harm reduction for injecting drug users; elimination of mother-to-child transmission [
      <xref rid="pmed.1002735.ref018" ref-type="bibr">18</xref>].
     </td>
    </tr>
    <tr>
     <td align="center" rowspan="1" colspan="1">
      <bold>Diagnosis</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">Parasite-based diagnostic testing—can either be by microscopy or rapid diagnostic test—for which results can be available within 30 minutes [
      <xref rid="pmed.1002735.ref005" ref-type="bibr">5</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Most countries still rely on sputum smear microscopy; however, microscopy detects only half the number of TB cases and cannot detect drug resistance. Since 2010, the rapid test Xpert MTB/RIF has become more available. Diagnosis can be made within 2 hours, requires less technical expertise, and can detect resistant strains [
      <xref rid="pmed.1002735.ref006" ref-type="bibr">6</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Clinical diagnosis is based on complete skin examination, involving identification of skin lesions, peripheral nerve involvement, or motor weakness and sensory loss. Laboratory diagnosis is through identification of acid-fast bacilli in slit skin smears or by full thickness skin biopsy. In practice, laboratory studies are not essential for the diagnosis of leprosy, although confirmation by skin biopsy is recommended [
      <xref rid="pmed.1002735.ref019" ref-type="bibr">19</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Serological tests (e.g., rapid diagnostic tests or enzyme immunoassays) can detect the presence or absence of antibodies to HIV-1/2 and/or the HIV p24 antigen [
      <xref rid="pmed.1002735.ref020" ref-type="bibr">20</xref>]. HIV self-testing does not provide a definitive diagnosis but is an initial test that requires further testing by a health worker using a nationally validated testing algorithm [
      <xref rid="pmed.1002735.ref021" ref-type="bibr">21</xref>].
     </td>
    </tr>
    <tr>
     <td align="center" rowspan="1" colspan="1">
      <bold>Treatment</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">Malaria is curable. For 
      <italic>P</italic>. 
      <italic>falciparum</italic>, malaria ACT is recommended [
      <xref rid="pmed.1002735.ref005" ref-type="bibr">5</xref>]. However, counterfeit antimalarials are an increasing global problem [
      <xref rid="pmed.1002735.ref022" ref-type="bibr">22</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">The great majority of TB cases can be cured by four antimicrobial drugs taken properly over 6 months. However, MDR TB and extensively drug-resistant TB do not respond as well to second-line treatments and can require 2 or more years of treatment. In 2016, 35 Asian and African countries saw the introduction of new second-line drugs that have shortened the length of MDR TB regimens [
      <xref rid="pmed.1002735.ref006" ref-type="bibr">6</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">MDT—combined chemotherapy with rifampicin, dapsone, and clofazimine—is available free of charge to most countries from WHO or through national health programmes. The number of skin lesions is used to guide treatment. The standard WHO regimens are (a) a 12-month oral course of MDT for adults with more than five skin lesions and (b) a 6-month oral course of rifampicin and dapsone for adults with two to five skin lesions [
      <xref rid="pmed.1002735.ref023" ref-type="bibr">23</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Combination ART consisting of three or more ARV drugs can control the virus by lowering viral load and helping prevent onward transmission. New WHO guidelines in 2016 recommended provision of lifelong ART to all children, adolescents, and adults, including all pregnant and breastfeeding women living with HIV, regardless of CD4 cell count [
      <xref rid="pmed.1002735.ref024" ref-type="bibr">24</xref>].
     </td>
    </tr>
    <tr>
     <td align="center" rowspan="1" colspan="1">
      <bold>Resistance</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">Vector control is dependent on the use of pyrethroids, the only class of insecticides recommended for ITNs or LLINs. Mosquito resistance to pyrethroids has emerged, but there is believed to be no decreased efficacy of LLINs. Rotational use of different classes of insecticides for indoor spraying is one approach to managing resistance [
      <xref rid="pmed.1002735.ref005" ref-type="bibr">5</xref>].
      <break/>Resistance to antimalarial medicines is also a recurring problem, with chloroquine and sulfadoxine-pyrimethamine (SP) developing resistance in the 1950s and 1960s. Recently, parasite resistance to artemisinin has been detected in five countries of the Greater Mekong subregion [
      <xref rid="pmed.1002735.ref005" ref-type="bibr">5</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">Resistant TB strains have developed through the use of incorrect prescriptions, poor quality drugs, and patients stopping treatment prematurely.
      <break/>MDR TB is resistance to two of the most powerful first-line drugs, rifampicin and isoniazid. In 2016, there were 490,000 people with MDR TB, approximately half of whom lived in China, India, or the Russian Federation, but only 54% were successfully treated. In 2016, about 6.2% of MDR TB cases had XDR TB, which means resistant to second-line drugs, and only 30% were successfully treated [
      <xref rid="pmed.1002735.ref006" ref-type="bibr">6</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">In the 1960s, 
      <italic>M</italic>. 
      <italic>leprae</italic> started to develop resistance to dapsone, the world’s only known anti-leprosy drug at that time. Today, there are ‘a few isolated reports of rifampicin-resistant leprosy, mainly from areas where rifampicin was given as monotherapy, either alone or in combination with dapsone, to dapsone-resistant patients’ [
      <xref rid="pmed.1002735.ref025" ref-type="bibr">25</xref>]. Resistance to rifamipicin, the most important component of MDT, appears to be associated with noncompliance with dapsone or clofazimine regimens.
     </td>
     <td align="left" rowspan="1" colspan="1">HIV drug resistance rapidly appears if only one or two ARV drugs are used, if treatment adherence is poor, or if there are interruptions in treatment. The rollout of ART has been accompanied by increases in resistance at the population level; research has shown that in the first 10 years (2001–2011) of mass treatment rollout, non-nucleoside reverse transcriptase inhibitors resistance increased by 36% per year in East Africa and by 23% in Southern Africa [
      <xref rid="pmed.1002735.ref026" ref-type="bibr">26</xref>]. A recent WHO report found that urgent attention is needed to decrease levels of loss to follow-up, support retention, maximise adherence, and prevent drug stock outs [
      <xref rid="pmed.1002735.ref027" ref-type="bibr">27</xref>].
     </td>
    </tr>
    <tr>
     <td align="center" rowspan="1" colspan="1">
      <bold>Vaccine development</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">More than 30 
      <italic>P</italic>. 
      <italic>falciparum</italic> malaria vaccine candidates are at advanced preclinical or clinical stages of evaluation, but only the RTS,S/AS01 vaccine has completed Phase 3 trials and passed a positive regulatory assessment. In November 2016, WHO announced that the RTS,S vaccine would be rolled out in pilot projects in three countries in sub-Saharan Africa [
      <xref rid="pmed.1002735.ref005" ref-type="bibr">5</xref>]. Potential shortcomings of the vaccine are that it is partially effective and requires three primary doses followed by a booster [
      <xref rid="pmed.1002735.ref028" ref-type="bibr">28</xref>]. Of the trial participants given a four-dose schedule starting at 5–17 months of age, vaccine efficacy against severe malaria was 31.5% (95% CI 9.3–48.3) over about 4 years of follow-up [
      <xref rid="pmed.1002735.ref029" ref-type="bibr">29</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">BCG vaccine does prevent infection and is partially effective in preventing miliary TB in young children. A new vaccine that can prevent infection is key to addressing the reservoir of infection required to achieve the End TB strategy. There are 16 different TB vaccine candidates, but none have passed Phase II trials yet [
      <xref rid="pmed.1002735.ref030" ref-type="bibr">30</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">BCG vaccine has a protective effect against leprosy. One meta-analysis suggested an overall protective effect of 26% based on seven experimental studies [
      <xref rid="pmed.1002735.ref031" ref-type="bibr">31</xref>]. Trials are underway in India to investigate protection provided by a vaccine based on 
      <italic>M</italic>. 
      <italic>indicus pranii</italic> [
      <xref rid="pmed.1002735.ref032" ref-type="bibr">32</xref>].
     </td>
     <td align="left" rowspan="1" colspan="1">HIV vaccine development is complicated by the extreme variability of the virus and, in particular, its envelope protein at both the individual and population level. A large multiyear clinical trial (HVTN 702) of a new vaccine is currently underway in South Africa [
      <xref rid="pmed.1002735.ref033" ref-type="bibr">33</xref>].
     </td>
    </tr>
   </tbody>
  </table>
 </alternatives>
 <table-wrap-foot>
  <fn id="t002fn001">
   <p>Abbreviations: ACT, artemisinin-based combination therapy; ART, antiretroviral therapy; ARV, antiretroviral; BCG, bacille Calmette-Guérin vaccine; HVTN, HIV Vaccine Trials Network; ITN, insecticide-treated bednet; LLIN, long-lasting insecticide-treated bednet; LMIC, low- or middle-income country; MDR TB, multidrug-resistant TB; MDT, multidrug therapy; SP, sulphadoxine-pyrimethamine; STI, sexually transmitted infection; TB, tuberculosis; XDR TB, extensively drug-resistant tuberculosis.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
